Skip to main content
. Author manuscript; available in PMC: 2018 Nov 15.
Published in final edited form as: Clin Cancer Res. 2017 Sep 12;23(22):7072–7083. doi: 10.1158/1078-0432.CCR-17-0413

Figure 1. Concurrent TOP2A and EZH2 expression is associated with biochemical recurrence and a mitotic gene signature.

Figure 1

(A) Unsupervised clustering analysis of TCGA primary prostate cancer data demonstrates that patients with concurrent high TOP2A and EZH2 expression (TOP2A+/EZH2+; green) tightly cluster apart from other patients (purple) based on their differentially expressed genes (DEGs). (B) Unique DEGs between TOP2A+/EZH2+ and other patients was validated by principle component analysis (PCA). (C) Kaplan-Meier curves reveals that TOP2A+/EZH2+ patients have a faster progression to biochemical recurrence. (D) Comparison of DEGs in TOP2A+/EZH2+ patients versus other patients in TCGA (2015) and Taylor et al. (2010) independent primary datasets. (E) Gene Set Enrichment Analysis (GSEA) revealed statistically significant overlapping gene signatures involved in mitosis and E2F signaling (P < 0.05 and FDR < 0.15; Supplement Table 2).